Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sucampo Pharmaceuticals Inc (NASDAQ:SCMP)

Delayed Data
As of Oct 09
 -1.21 / -6.24%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Major

Company Description

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders, as well as other therapeutic applications of drug technologies. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. The company was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.

Contact Information

Sucampo Pharmaceuticals, Inc.
4520 East-West Highway
Bethesda Maryland 20814-3392
P:(301) 961-3400
Investor Relations:
(240) 223-3718



Individual stakeholders70.95%
Other institutional25.88%
Mutual fund holders21.42%

Top Executives

Peter S. GreenleafChief Executive Officer & Director
Andrew P. SmithChief Financial Officer
Peter LichtlenChief Medical Officer
Peter Alec KienerChief Scientific Officer
Matthias A. AlderSecretary, General Counsel & Executive VP